Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Fig. 1

Family history data collection. All oncological disease with malignant potential, both hematological and solid, were screened. Lineal line (descendants or ascendants) and collateral line (non-descentants/ascendants e.g., brothers/sisters) were screened till the second degree (grandparents for lineal line and brothers/sisters for the collateral line). Patients were categorized as follow: FHC-high (in case of at least one cancer diagnosis in both lineal and collateral family lines), FHC-low (in case of at least one cancer diagnosis in either the lineal or collateral line) and FHC-negative (Fig. 1). On the basis of our previous findings (Ref. [4]), FHC-high was considered the group of interest for all analyses

Back to article page